NasdaqCM:HJLI

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Hancock Jaffe Laboratories

Executive Summary

Hancock Jaffe Laboratories, Inc., a development stage company, develops and sells biological based tissue solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. More Details


Snowflake Analysis

Adequate balance sheet with weak fundamentals.

Share Price & News

How has Hancock Jaffe Laboratories's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HJLI's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-10.4%

HJLI

0.6%

US Medical Equipment

0.08%

US Market


1 Year Return

-51.9%

HJLI

14.8%

US Medical Equipment

12.8%

US Market

Return vs Industry: HJLI underperformed the US Medical Equipment industry which returned 14.8% over the past year.

Return vs Market: HJLI underperformed the US Market which returned 12.8% over the past year.


Shareholder returns

HJLIIndustryMarket
7 Day-10.4%0.6%0.08%
30 Day-8.5%1.2%-1.8%
90 Day-3.6%11.5%7.2%
1 Year-51.9%-51.9%15.8%14.8%15.3%12.8%
3 Yearn/a72.3%67.9%39.2%29.9%
5 Yearn/a148.2%129.3%88.3%67.1%

Price Volatility Vs. Market

How volatile is Hancock Jaffe Laboratories's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Hancock Jaffe Laboratories undervalued compared to its fair value and its price relative to the market?

27.29x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate HJLI's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate HJLI's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: HJLI is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: HJLI is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate HJLI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: HJLI is overvalued based on its PB Ratio (27.3x) compared to the US Medical Equipment industry average (4.1x).


Next Steps

Future Growth

How is Hancock Jaffe Laboratories forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-17.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HJLI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: HJLI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: HJLI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: HJLI is forecast to have no revenue next year.

High Growth Revenue: HJLI is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if HJLI's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Hancock Jaffe Laboratories performed over the past 5 years?

-14.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HJLI is currently unprofitable.

Growing Profit Margin: HJLI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: HJLI is unprofitable, and losses have increased over the past 5 years at a rate of 14.1% per year.

Accelerating Growth: Unable to compare HJLI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HJLI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.2%).


Return on Equity

High ROE: HJLI has a negative Return on Equity (-1865.6%), as it is currently unprofitable.


Next Steps

Financial Health

How is Hancock Jaffe Laboratories's financial position?


Financial Position Analysis

Short Term Liabilities: HJLI's short term assets ($1.8M) do not cover its short term liabilities ($3.0M).

Long Term Liabilities: HJLI's short term assets ($1.8M) exceed its long term liabilities ($410.9K).


Debt to Equity History and Analysis

Debt Level: HJLI's debt to equity ratio (84.6%) is considered high.

Reducing Debt: HJLI had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HJLI has sufficient cash runway for 3 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: HJLI is forecast to have sufficient cash runway for 3 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is Hancock Jaffe Laboratories's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HJLI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HJLI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HJLI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HJLI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HJLI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.4yrs

Average management tenure


CEO

Robert Berman (57 yo)

2.42yrs

Tenure

US$415,285

Compensation

Mr. Robert A. Berman serves as Chief Executive Officer and Director of Hancock Jaffe Laboratories, Inc. since April 2018. From September 2017 to March 2018, Mr. Berman worked as an independent strategic bu ...


CEO Compensation Analysis

Compensation vs Market: Robert's total compensation ($USD415.29K) is about average for companies of similar size in the US market ($USD589.30K).

Compensation vs Earnings: Robert's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Robert Berman
CEO & Director2.42yrsUS$415.29k2.88%
$ 485.9k
Marc Glickman
Senior VP & Chief Medical Officer4.33yrsUS$422.02k0.75%
$ 126.3k
Warren Hancock
Co-founder33.67yrsno datano data
Craig Glynn
Interim CFO & Interim Treasurer0.42yrno datano data
Benedict Broennimann
Chief Medical Officer of Outside of United States2.33yrsUS$240.00k0%
$ 0

2.4yrs

Average Tenure

61yo

Average Age

Experienced Management: HJLI's management team is considered experienced (2.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Robert Berman
CEO & Director2.42yrsUS$415.29k2.88%
$ 485.9k
Robert Gray
Independent Director1yrUS$82.80k0.039%
$ 6.6k
Matthew Jenusaitis
Independent Director1yrUS$82.80k0.037%
$ 6.3k
Afksendyios Kalangos
Member of Medical Advisory Boardno datano datano data
Francis Duhay
Independent Director1.92yrsUS$91.09k0.11%
$ 18.8k
Steve Elias
Member of Medical Advisory Boardno datano datano data
Antonios Gasparis
Member of Medical Advisory Boardno datano datano data
Wade Dimitri
Member of Medical Advisory Boardno datano datano data
Sanjay Shrivastava
Independent Director1.92yrsUS$91.09k0.087%
$ 14.7k

1.9yrs

Average Tenure

58yo

Average Age

Experienced Board: HJLI's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 123.7%.


Top Shareholders

Company Information

Hancock Jaffe Laboratories, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Hancock Jaffe Laboratories, Inc.
  • Ticker: HJLI
  • Exchange: NasdaqCM
  • Founded: 1987
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$16.881m
  • Shares outstanding: 40.10m
  • Website: https://www.hancockjaffe.com

Number of Employees


Location

  • Hancock Jaffe Laboratories, Inc.
  • 70 Doppler
  • Irvine
  • California
  • 92618
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HJLINasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDMay 2018
5HJBST (Boerse-Stuttgart)YesCommon StockDEEURMay 2018

Biography

Hancock Jaffe Laboratories, Inc., a development stage company, develops and sells biological based tissue solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in t ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/21 06:23
End of Day Share Price2020/09/18 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.